Diversified Healthcare Trust (DHC) has been rated a 'Buy' due to improved fundamentals and a stronger balance sheet despite recent share price gains. In Q2 2026, its SHOP segment's net operating income rose 37.2% year-over-year, with normalized funds from operations (FFO) surging 109.4% to $0.16 per share. The company has successfully reduced leverage, with net debt to adjusted EBITDAre falling to 7.1x, no major debt maturities until 2028, and $270 million in liquidity. DHC prioritizes balance sheet strength over dividends, supported by SHOP segment growth and a supply-demand imbalance, making it an attractive investment opportunity.
Purepoint Uranium Group reported significant radioactivity in the first drill hole at the Q24 target of its Dorado project, with 7.4 meters at 8,760 counts per second and peaks up to 50,000 cps. This discovery is important as it confirms uranium pres...
The iShares MBS ETF (MBB), with $38.85 billion in assets, is exposed to downside risk due to rising intermediate-term interest rates and persistent inflation pressures. Its effective duration of 5.68 years makes it vulnerable to potential rate hikes,...
Nicholas Crypto Income ETF (BLOX) holds a Hold rating due to a recent recovery in cryptocurrency prices, yet it remains vulnerable to sharp declines. The fund's trailing yield is 44%, but this is backward-looking, with the current distribution rate a...
Shares of Saul Centers have fallen nearly 20% recently, prompting an upgrade to 'buy' for income-focused investors. Despite pressure from higher interest rates and leverage, most of the company's debt is fixed-rate or hedged, reducing risk. The ramp-...
BlackBerry's stock is upgraded to Buy ahead of its Q2 earnings report after strong Q1 results and improving growth metrics, especially in its QNX segment which posted record developer license revenue and has nearly $1 billion in royalty backlog. The ...
